Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr Porter on the Efficacy of CAR T-Cell Therapy in Relapsed/Refractory CLL

May 9th 2024

David L. Porter, MD, discusses the use of CAR T-cell therapy alone or in combination regimens in relapsed/refractory chronic lymphocytic leukemia.

Dr Deng on BTK Inhibitors vs Venetoclax-Based Treatment Regimens in CLL/SLL

May 9th 2024

Changchun Deng, MD, PhD, discusses considerations for covalent BTK inhibitors vs venetoclax-based treatment regimens for chronic lymphocytic leukemia.

Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL

May 7th 2024

Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.

Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL

May 6th 2024

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.

Dr Deng on the Benefits of Pirtobrutinib in CLL

May 4th 2024

Changchun Deng, MD, PhD, discusses the mechanism of action and advantageous features of pirtobrutinib for patients with chronic lymphocytic leukemia.

Risk Factors Could Inform BTK Inhibitor and Venetoclax Sequencing in CLL/SLL

May 2nd 2024

Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates

April 18th 2024

Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.

BTK Inhibitor Selection for CLL/SLL Is Evolving in Community Settings

April 15th 2024

A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL

April 12th 2024

A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

Dr Dholaria on the Use of Liso-Cel in Relapsed/Refractory CLL

April 10th 2024

Bhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.

Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL

April 9th 2024

Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.

Dr Kenderian on the Efficacy of Liso-Cel in R/R CLL/SLL

April 6th 2024

Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.

Dr Sotomayor on the Integration of BTK Inhibitors into the CLL Treatment Arsenal

March 29th 2024

Eduardo Sotomayor, MD, discusses the current arsenal of BTK inhibitors in chronic lymphocytic leukemia.

Dr Kenderian on Moving Liso-Cel to the First Line of CLL Treatment

March 28th 2024

Saad J. Kenderian, MB, CHB, discusses ongoing research taking place to potentially move liso-cel into earlier lines of therapy for patients with CLL.

A Groundbreaking First in CLL/SLL: Liso-Cel Makes its Mark as Only CAR T-Cell Therapy Approved

March 25th 2024

Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Brown on the Implications of Genomic Data for Pirtobrutinib Use in CLL

March 25th 2024

Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.

MRD-Directed Ibrutinib Plus Venetoclax Bests FCR in CLL

March 20th 2024

MRD-guided ibrutinib plus venetoclax displays PFS and OS benefits over fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in February 2024.